CGEM Cullinan Management Inc.

38.18
+0.35  (+1%)
Previous Close 37.83
Open 37.98
52 Week Low 27.01
52 Week High 43
Market Cap $1,444,396,629
Shares 37,831,237
Float 22,368,247
Enterprise Value $1,062,130,309
Volume 199,900
Av. Daily Volume 131,014
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
CLN-081
Non-Small Cell Lung Cancer
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
CLN-619
Solid tumors
Phase 1
Phase 1
Phase 1 IND filing due 1H 2021.
CLN-049
Acute myeloid leukemia (AML)
Phase 1
Phase 1
Phase 1 IND filing due 1Q 2021.

Latest News

  1. CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cullinan Management, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, today announced the closing of its initial public offering of 13,685,000 shares of its common stock, including 1,785,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a price to the public of $21.00 per share. The gross proceeds of the offering were $287.4 million, before deducting underwriting discounts and commissions and other offering expenses. The shares began trading on the Nasdaq Global Select Market on January 8…

    CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cullinan Management, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, today announced the closing of its initial public offering of 13,685,000 shares of its common stock, including 1,785,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a price to the public of $21.00 per share. The gross proceeds of the offering were $287.4 million, before deducting underwriting discounts and commissions and other offering expenses. The shares began trading on the Nasdaq Global Select Market on January 8, 2021 under the symbol "CGEM." All shares in the offering were offered by Cullinan Management.

    Morgan Stanley & Co. LLC, SVB Leerink LLC, and Evercore Group LLC acted as joint book-running managers for the offering. H.C. Wainwright & Co., LLC acted as lead manager for the offering.

    Registration statements relating to these securities have been filed and were declared effective by the Securities and Exchange Commission on January 7, 2021. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132, or by email at ; and Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at (888) 474 0200, or by email at .

    This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.

    About Cullinan Management

    Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company's strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.

    Contacts:

    Investor Relations

    Jeff Trigilio

    +1 716.725.5019



    Primary Logo

    View Full Article Hide Full Article
  2. CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Management, Inc., a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, announced today the pricing of its upsized initial public offering of 11,900,000 shares of common stock at a price to the public of $21.00 per share. All shares are being offered by Cullinan Management. The gross proceeds to Cullinan Management from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $249.9 million. In addition, the underwriters have a 30-day option to purchase up to an additional 1,785,000 shares…

    CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Management, Inc., a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, announced today the pricing of its upsized initial public offering of 11,900,000 shares of common stock at a price to the public of $21.00 per share. All shares are being offered by Cullinan Management. The gross proceeds to Cullinan Management from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $249.9 million. In addition, the underwriters have a 30-day option to purchase up to an additional 1,785,000 shares of common stock at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market under the ticker symbol "CGEM" on January 8, 2021. The offering is expected to close on January 12, 2021, subject to the satisfaction of customary closing conditions.

    Morgan Stanley & Co. LLC, SVB Leerink LLC, and Evercore Group LLC are acting as joint book-running managers for the offering. H.C. Wainwright & Co., LLC is acting as lead manager for the offering.

    A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on January 7, 2021. The offering is being made only by means of a written prospectus. Copies of the final prospectus relating to the initial public offering can be obtained, when available, from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132, or by email at ; and Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at (888) 474 0200, or by email at .

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Cullinan Management



    Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company's strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.

    Contacts:



    Investor Relations

    Jeff Trigilio

    +1 716.725.5019



    Primary Logo

    View Full Article Hide Full Article
View All Cullinan Management Inc. News